STAAR Surgical Company (STAA)

Mixed-but-improving: a pristine net-cash balance sheet ($181.5M cash and investments, zero borrowings) and a GAAP-confirmed FY2026 turnaround (H1 revenue +115.2% to $187.1M, net income $13.3M, two straight profitable quarters) are weighed against extreme China distributor concentration (56% of sales, 65% of receivables), still-negative trailing free cash flow, and a brief profit track record. No dividend event risk. Verdict: a recovering watchlist candidate — improving, but not yet de-risked.

STAAR Surgical is a mixed, forming setup: the dominant in-window catalyst is a Stifel upgrade to Buy with the target raised to $31 (announced, only partially priced), set against a genuinely split analyst and media tape. The sentiment delta is determinate but mildly negative (baseline +0.19 to scoring +0.06 - cooling, not improving), so a moderate red-flag cap applies for conflicting catalyst signals; no severe flags, and the first-party PR feed was unavailable this run (extraction failure), leaving the catalyst map to third-party sources.

Do Nothing - event-suppressed entry, with an independently non-qualifying chart. Decisive block: ticker-filtered calendars returned a confirmed Q3 FY2026 earnings date of 2026-11-04 (amc) which lands on the 15th trading day of the holding window (horizon_date 2026-11-04 from calc_trading_days_forward, inclusive) - an unhedgeable gap inside the intended hold. Chart-side: the 2026-10-13 close 21.50 sits below every tracked average - SMA20 21.51, SMA50 22.81, SMA200 23.59, EMA9 21.92, EMA21 22.01, WMA9 22.02, WMA21 21.76, DEMA14 21.86, TEMA14 22.07 - and below the 10-13 VWAP 21.68, with RSI14 44.75 (below midline, not oversold) and ADX14 16.41 (trendless, down from 26.38 on 09-30). The lone repair signal is MACD (line -0.21 above signal -0.32, histogram +0.11 off its 0.29 peak, repaired from -0.66 on 09-30) but it remains below zero, so any pullback/oversold limit is countertrend under both trend-alignment clauses (price < SMA50 with MACD < 0; price < SMA200 with SMA50 < SMA200 and no momentum reclaim), and no momentum-breakout stop exists (two-week range 21.24-22.97, lower highs into 22.5-23.0 overhead supply; a range-top trigger ~23.00 computes R/R ~0.99). Chart quality 2/5 - below the 3/5 entry floor. Every quantitative gate otherwise passes (liquidity ADV20 $21.71M and recent 3-session ~$8.8M; max overnight gap 0.86%; ATR14 0.97 = 4.51% of price; all indicators loaded; bar vintage 2026-10-13, lag 1 trading day). Verdict: Do Nothing; action fields at defaults, technicals preserved.